Astrazeneca's share price declined sharply in early trading today, falling six per cent to 11,866p. This follows reports that the UK drugmaker is exploring a possible $400bn merger with its US rival, Bristol Myers Squibb.
The FTSE 100 company has reportedly been in talks with the US group in recent months over a potential tie-up. However, this initial market reaction contrasts with typical share price spikes seen in similar FTSE takeovers and mergers, which often occur as investors anticipate positive outcomes.
Richard Hunter, head of markets at Interactive Investor, suggested the share price movement sends "a clear signal that investors would potentially be opposed to such a deal." He noted that the deal raises questions about Astrazeneca's commitment to the UK, particularly as chief executive Pascal Soriot has previously referred to the drugmaker as a "very American company" and has focused on expanding its US operations.
Russ Mould, investment director at AJ Bell, stated that a merger of this scale could have implications beyond the pharmaceutical sector. He added that there are fears such a move, combined with the company's recent direct listing in New York, could shift its focus across the Atlantic, potentially leading to the UK stock market losing one of its major companies.
Concerns have also been raised about the size of the proposed $400bn deal, which would exceed past transactions such as the Vodafone and Mannesmann merger in 2000, valued at approximately $350bn. Mould highlighted that major transactions often face difficulties, including integration challenges and potential antitrust scrutiny, particularly in the US, given the overlapping focus of both companies in oncology.